NASDAQ:VLON

Vallon Pharmaceuticals Competitors

$4.87
-0.25 (-4.88 %)
(As of 04/14/2021 05:20 PM ET)
Add
Compare
Today's Range
$4.72
Now: $4.87
$5.15
50-Day Range
$4.32
MA: $5.20
$6.89
52-Week Range
$4.30
Now: $4.87
$9.90
Volume44,861 shs
Average Volume80,964 shs
Market Capitalization$33.17 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Vallon Pharmaceuticals (NASDAQ:VLON) Vs. LGVN, EVAX, UPC, VRDN, IKT, and VIRI

Should you be buying VLON stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Vallon Pharmaceuticals, including Longeveron (LGVN), Evaxion Biotech A/S (EVAX), Universe Pharmaceuticals (UPC), Viridian Therapeutics (VRDN), Inhibikase Therapeutics (IKT), and Virios Therapeutics (VIRI).

Longeveron (NASDAQ:LGVN) and Vallon Pharmaceuticals (NASDAQ:VLON) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Profitability

This table compares Longeveron and Vallon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LongeveronN/AN/AN/A
Vallon PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Longeveron and Vallon Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Longeveron0000N/A
Vallon Pharmaceuticals0000N/A

Valuation & Earnings

This table compares Longeveron and Vallon Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LongeveronN/AN/AN/AN/AN/A
Vallon PharmaceuticalsN/AN/AN/AN/AN/A

Evaxion Biotech A/S (NASDAQ:EVAX) and Vallon Pharmaceuticals (NASDAQ:VLON) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Valuation & Earnings

This table compares Evaxion Biotech A/S and Vallon Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evaxion Biotech A/SN/AN/AN/AN/AN/A
Vallon PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Evaxion Biotech A/S and Vallon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evaxion Biotech A/SN/AN/AN/A
Vallon PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Evaxion Biotech A/S and Vallon Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evaxion Biotech A/S00203.00
Vallon Pharmaceuticals0000N/A

Evaxion Biotech A/S presently has a consensus target price of $18.00, indicating a potential upside of 146.24%. Given Evaxion Biotech A/S's higher possible upside, analysts plainly believe Evaxion Biotech A/S is more favorable than Vallon Pharmaceuticals.

Summary

Evaxion Biotech A/S beats Vallon Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Universe Pharmaceuticals (NYSE:UPC) and Vallon Pharmaceuticals (NASDAQ:VLON) are both small-cap companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Valuation and Earnings

This table compares Universe Pharmaceuticals and Vallon Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe PharmaceuticalsN/AN/AN/AN/AN/A
Vallon PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Universe Pharmaceuticals and Vallon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Universe PharmaceuticalsN/AN/AN/A
Vallon PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Universe Pharmaceuticals and Vallon Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Universe Pharmaceuticals0000N/A
Vallon Pharmaceuticals0000N/A

Viridian Therapeutics (NASDAQ:VRDN) and Vallon Pharmaceuticals (NASDAQ:VLON) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Profitability

This table compares Viridian Therapeutics and Vallon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viridian TherapeuticsN/AN/AN/A
Vallon PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Viridian Therapeutics and Vallon Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viridian Therapeutics00203.00
Vallon Pharmaceuticals0000N/A

Viridian Therapeutics presently has a consensus target price of $34.00, indicating a potential upside of 132.56%. Given Viridian Therapeutics' higher possible upside, equities research analysts clearly believe Viridian Therapeutics is more favorable than Vallon Pharmaceuticals.

Valuation and Earnings

This table compares Viridian Therapeutics and Vallon Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridian TherapeuticsN/AN/AN/AN/AN/A
Vallon PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Viridian Therapeutics beats Vallon Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Vallon Pharmaceuticals (NASDAQ:VLON) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares Vallon Pharmaceuticals and Inhibikase Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vallon PharmaceuticalsN/AN/AN/A
Inhibikase TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Vallon Pharmaceuticals and Inhibikase Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vallon Pharmaceuticals0000N/A
Inhibikase Therapeutics0000N/A

Valuation & Earnings

This table compares Vallon Pharmaceuticals and Inhibikase Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vallon PharmaceuticalsN/AN/AN/AN/AN/A
Inhibikase TherapeuticsN/AN/AN/AN/AN/A

Vallon Pharmaceuticals (NASDAQ:VLON) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares Vallon Pharmaceuticals and Virios Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vallon PharmaceuticalsN/AN/AN/A
Virios TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Vallon Pharmaceuticals and Virios Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vallon Pharmaceuticals0000N/A
Virios Therapeutics0000N/A

Valuation & Earnings

This table compares Vallon Pharmaceuticals and Virios Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vallon PharmaceuticalsN/AN/AN/AN/AN/A
Virios TherapeuticsN/AN/AN/AN/AN/A


Vallon Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
LGVN
Longeveron
0.3$7.49-2.3%$136.94 millionN/A0.00News Coverage
Gap Up
EVAX
Evaxion Biotech A/S
1.7$7.33-11.2%$124.99 millionN/A0.00News Coverage
Gap Down
UPC
Universe Pharmaceuticals
0.0$3.92-4.3%$88.96 millionN/A0.00Gap Down
VRDN
Viridian Therapeutics
1.7$14.46-6.3%$60.07 millionN/A0.00Decrease in Short Interest
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.31-2.3%$54.58 millionN/A0.00Gap Up
VIRI
Virios Therapeutics
1.3$5.90-0.8%$48.73 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.29-2.1%$37.93 millionN/A0.00Gap Down
VRPX
Virpax Pharmaceuticals
0.3$4.62-2.4%$23.39 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$35.01-12.4%$16.25 millionN/A0.00Gap Up
VYNT
Vyant Bio
0.0$3.84-4.9%$14.91 millionN/A0.00
BCTX
BriaCell Therapeutics
0.0$3.20-12.8%$2.79 millionN/A0.00News Coverage
Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.73-5.5%$0.00N/A0.00Gap Down
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.81-2.8%$0.00N/A0.00News Coverage
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08-0.0%$0.00N/A0.00
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06-0.0%$0.00N/A0.00Increase in Short Interest
News Coverage
RPHM
Reneo Pharmaceuticals
0.3$12.32-0.7%$0.00N/A0.00Insider Buying
News Coverage
SCPS
Scopus BioPharma
1.4$7.82-0.4%$0.00N/A0.00Increase in Short Interest
VECT
VectivBio
0.0$16.65-4.9%$0.00N/A0.00News Coverage
Gap Up
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.